Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EPS (Weighted Average and Diluted): 2009-2025

Historic EPS (Weighted Average and Diluted) for Cytokinetics (CYTK) over the last 7 years, with Sep 2025 value amounting to -$2.55.

  • Cytokinetics' EPS (Weighted Average and Diluted) fell 87.50% to -$2.55 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.29, marking a year-over-year decrease of 16.91%. This contributed to the annual value of -$5.26 for FY2024, which is 3.49% up from last year.
  • As of Q3 2025, Cytokinetics' EPS (Weighted Average and Diluted) stood at -$2.55, which was down 127.68% from -$1.12 recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' EPS (Weighted Average and Diluted) peaked at -$0.23 during Q2 2022, and registered a low of -$2.55 during Q3 2025.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$1.35 (2023), whereas its average is -$1.43.
  • In the last 5 years, Cytokinetics' EPS (Weighted Average and Diluted) skyrocketed by 99.95% in 2021 and then tumbled by 482.61% in 2023.
  • Cytokinetics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.32 in 2021, then slumped by 362.50% to -$1.48 in 2022, then increased by 6.76% to -$1.38 in 2023, then increased by 8.70% to -$1.26 in 2024, then plummeted by 87.50% to -$2.55 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$2.55 for Q3 2025, versus -$1.12 for Q2 2025 and -$1.36 for Q1 2025.